Akeso Inc. Achieves First Annual Profit, Exceeding 1.85 Billion Yuan

In a significant milestone for Akeso Inc., the company has announced its first annual profit, surpassing 1.85 billion yuan. This achievement marks a remarkable turnaround for the company, which had reported a loss of approximately 1.42 billion yuan in the previous year. The profit can be attributed to the successful licensing partnership with Summit Therapeutics and the growing sales of innovative products such as Yida Fang® and Katanney®. Let's delve deeper into the factors behind Akeso Inc.'s success.

Akeso Inc. recently released its positive annual profit forecast, projecting a profit of no less than 1.85 billion yuan for the year 2023. The estimate is based on the unaudited comprehensive financial statements for the twelve months ending on December 31, 2023, and the available information from the board of directors. This anticipated profit marks a significant turning point for Akeso Inc., as it will be the company's first annual profit since its inception.

One of the primary drivers behind this remarkable achievement is the licensing partnership with Summit Therapeutics. Akeso Inc.'s core independently developed dual-targeted therapy, Yida Fang® (Ivosidenib/Venetoclax), gained overseas licensing rights through a collaboration with Summit Therapeutics. The transaction, valued at 5 billion U.S. dollars, includes upfront payments comprising a significant portion of the licensing fee, amounting to approximately 2.9 billion yuan. This substantial payment has been recognized as licensing revenue, contributing to Akeso Inc.'s profitability. The remaining portion of the upfront payment will be recognized as operational income in batches.

Another key contributor to Akeso Inc.'s success is the sales growth of its innovative product, Katanney® (Camrelizumab/Tremelimumab). With its outstanding clinical value, Katanney® has witnessed a continuous increase in the number of patients it serves, resulting in a steady rise in sales revenue. The company's commitment to scientific and efficient cost management has further propelled its success. Akeso Inc. has achieved a delicate balance between accelerating the development of innovative products and controlling costs, which has yielded positive outcomes.

Akeso Inc.'s achievement of its first annual profit, exceeding 1.85 billion yuan, signifies a significant milestone for the company. The success can be attributed to the strategic licensing partnership with Summit Therapeutics and the strong sales performance of innovative products like Yida Fang® and Katanney®. Akeso Inc.'s transformation from a loss-making entity to a profitable company demonstrates its commitment to scientific advancement, cost management, and delivering high-quality treatments to patients. As it continues to make strides in the pharmaceutical industry, Akeso Inc. sets a promising precedent for future growth and success.